 

Active ingredient: Baclofen 

 

Form/Route: Tablet/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 

Design: Single-dose, two-way crossover in-vivo 

Strength: 20 mg 

Subjects: Healthy males and nonpregnant females, general population 

Additional Comments: 




__________________________________________________________________________ 

 

2. Type of study: Fed 

Design: Single-dose, two-way crossover in-vivo 

Strength: 20 mg 

Subjects: Healthy males and females, general population 

Additional Comments: 




___________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Baclofen in plasma 

 

Bioequivalence based on (90% CI): Baclofen 

 

Waiver request of in-vivo testing: 10 mg based on (i) acceptable bioequivalence studies on the 
20 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) 
acceptable in vitro dissolution testing of all strengths. 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution 
information for this product at this website. Please conduct comparative dissolution testing on 12 
dosage units each of all strengths of the test and reference products. Specifications will be 
determined upon review of the application. 

 


